Visualizing Beta Cells After Islet Transplantation (GLP1-transpl)

January 29, 2022 updated by: Radboud University Medical Center

Visualizing Beta Cells After Intrahepatic Islet of Langerhans Transplantation

In patients with type 1 diabetes (T1D) that have undergone islet of Langerhans transplantation or are on the waiting list for transplantation, Ga-68-exendin PET imaging is performed to study the visualization of transplanted islet grafts in patients.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

Detecting damage to islets with a reliable imaging technique could be important for improving islet survival after transplantation. This could lead to better patient outcomes which would be of great interest for the treatment of type 1 diabetes. In order to assess the possibility of visualizing transplanted islet grafts with Ga-68-NODAGA-exendin-4 PET, a proof-of -concept study is performed in 10 patients with type 1 diabetes who have undergone intrahepatic islet transplantation with biochemically proven functional islet grafts and 5 patients with type 1 diabetes who are on the waiting list for islet transplantation. The investigators propose to determine the uptake of the radiolabeled tracer and compare it to functionality of the islet grafts. These highly relevant data will provide us with more information on the suitability of GLP-1 receptor imaging for monitoring of transplanted islet mass.

Study Type

Observational

Enrollment (Actual)

13

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Netherlands
    • Gelderland
      • Nijmegen, Gelderland, Netherlands, 6525 GA
        • Radboud University Medical Center
  • Sweden
      • Uppsala, Sweden, SE-751 85
        • Uppsala University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The population consists of 10 individuals with type 1 diabetes patients who have undergone intrahepatic islet transplantation at least 3 months earlier at. Furthermore, 5 T1D patients without an islet transplant will be included as a control for uptake of the radiotracer in the liver. All participating individuals need to be 18 years or older. In total, 15 participants will be included.

Description

Inclusion Criteria

Tx-group:

  • >18 years old
  • T1D patient undergone islet transplantation
  • Clinically proven functional islet graft
  • Signed informed consent

Control group:

  • >18 years old
  • T1D patients who are on the waiting list for islet transplantation
  • Signed informed consent

Exclusion Criteria:

  • Treatment with synthetic exendin or Dipeptidyl-Peptidase IV inhibitors within the last 3 months
  • Breast feeding
  • Pregnancy or the wish to become pregnant within 6 months
  • Kidney disease
  • Liver disease
  • Age <18 years
  • No signed informed consent

Exclusion criteria for MR:

  • fragments, clips or devices in brain, eyes, spinal canal
  • Implantable defibrillator or pacemaker (wires)
  • Mandibular magnetic implants
  • Neurostimulator, bladder stimulator, non-removable insulin pump
  • Metal tissue-expander in chest
  • Cochlear implant
  • Ossicular replacement prosthesis

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Tx-group
T1D patients that received islet of Langerhans transplantation (Tx) at least 3 months earlier
Radiation: 68Ga-NODAGA-exendin PET/CT
68Ga-NODAGA-exendin PET/CT
Control group
T1D patients that await islet of Langerhans transplantation
Radiation: 68Ga-NODAGA-exendin PET/CT
68Ga-NODAGA-exendin PET/CT

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hepatic uptake of 68Ga-NODAGA-exendin-4
Time Frame: 1 year
Hepatic uptake of 68Ga-NODAGA-exendin-4 obtained by quantitative analysis
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Islet graft function
Time Frame: 1 year
Correlation of tracer uptake and islet graft function
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Radboud University Medical Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 6, 2016

Primary Completion (Actual)

May 27, 2021

Study Completion (Actual)

May 27, 2021

Study Registration Dates

First Submitted

December 20, 2018

First Submitted That Met QC Criteria

December 20, 2018

First Posted (Actual)

December 24, 2018

Study Record Updates

Last Update Posted (Actual)

February 14, 2022

Last Update Submitted That Met QC Criteria

January 29, 2022

Last Verified

January 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NL52630.091.15

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Type 1 Diabetes Mellitus

Clinical Trials on 68Ga-NODAGA-exendin PET/CT

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe